Correlation Between Inozyme Pharma and Editas Medicine

Can any of the company-specific risk be diversified away by investing in both Inozyme Pharma and Editas Medicine at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inozyme Pharma and Editas Medicine into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Inozyme Pharma and Editas Medicine, you can compare the effects of market volatilities on Inozyme Pharma and Editas Medicine and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inozyme Pharma with a short position of Editas Medicine. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inozyme Pharma and Editas Medicine.

Diversification Opportunities for Inozyme Pharma and Editas Medicine

0.93

Correlation Coefficient

Inozyme Pharma  Editas Medicine

Almost no diversification

The 3 months correlation between Inozyme and Editas is 0.93. Overlapping area represents the amount of risk that can be diversified away by holding Inozyme Pharma and Editas Medicine in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Editas Medicine and Inozyme Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inozyme Pharma are associated (or correlated) with Editas Medicine. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Editas Medicine has no effect on the direction of Inozyme Pharma i.e., Inozyme Pharma and Editas Medicine go up and down completely randomly.

Pair Corralation between Inozyme Pharma and Editas Medicine

Given the investment horizon of 90 days Inozyme Pharma is expected to generate 0.73 times more return on investment than Editas Medicine. However, Inozyme Pharma is 1.37 times less risky than Editas Medicine. It trades about -0.1 of its potential returns per unit of risk. Editas Medicine is currently generating about -0.43 per unit of risk. If you would invest  343.00  in Inozyme Pharma on September 15, 2024 and sell it today you would lose (40.00) from holding Inozyme Pharma or give up 11.66% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Strong
Accuracy	100.0%
Values	Daily Returns

Inozyme Pharma  vs.  Editas Medicine

Inozyme Pharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Inozyme Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Editas Medicine

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Editas Medicine has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's forward indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Inozyme Pharma and Editas Medicine

The main advantage of trading using opposite Inozyme Pharma and Editas Medicine positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inozyme Pharma position performs unexpectedly, Editas Medicine can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Editas Medicine will offset losses from the drop in Editas Medicine's long position.

The idea behind Inozyme Pharma and Editas Medicine pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.